Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among k ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

No significant differences were seen in the odds of postoperative pneumonia between GLP-1 RA users and nonusers in an adjusted analysis (odds ratio, 0.78; 95% confidence interval, 0.57 to 1.06; P ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.

Glucagon-like peptide-1 (GLP-1) receptor agonists, or GLP-1 drugs, have quickly risen to popularity. They are already shaping food trends in major ways. But this could be only the beginning. The drugs ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. (HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment ...

Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.